SCOTT W WOODS, MD
Psychiatric in New Haven, CT

License number
Connecticut 025846
Category
Psychiatric
Type
Psychiatry
Address
Address
34 Park St Connecticut Mental Health Ctr, New Haven, CT 06519
Phone
(203) 974-7417
(203) 974-7413 (Fax)

Personal information

See more information about SCOTT W WOODS at radaris.com
Name
Address
Phone
Scott Woods, age 71
41 Half Mile Rd, Guilford, CT 06437
(203) 689-5261
Scott Woods, age 52
77 Northwood Rd, Newington, CT 06111
Scott Woods
110 Kane St #A2, West Hartford, CT 06119
Scott Woods
216 S Thames St, Norwich, CT 06360
(860) 887-7463
Scott Woods
660 Hillside Ave, Hartford, CT 06106
(860) 956-9293

Professional information

See more information about SCOTT W WOODS at trustoria.com
Scott W Woods Photo 1
Dr. Scott W Woods, New Haven CT - MD (Doctor of Medicine)

Dr. Scott W Woods, New Haven CT - MD (Doctor of Medicine)

Specialties:
Neuropsychiatry (Psychiatry)
Address:
Connecticut Mental Health Ctr
34 Park St, New Haven 06519
(203) 974-7300 (Phone)
Certifications:
Psychiatry, 1989
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Connecticut Mental Health Ctr
34 Park St, New Haven 06519
Yale - New Haven Hospital
20 York St, New Haven 06510
Education:
Medical School
Baylor University
Graduated: 1978
University Of California, Davis
Massachusetts General Hospital


Scott William Woods Photo 2
Scott William Woods, New Haven CT

Scott William Woods, New Haven CT

Specialties:
Psychiatry, Medical Oncology
Work:
Connecticut Mental Health Center
34 Park St, New Haven, CT 06519
Education:
Baylor College of Medicine (1978)


Scott Woods Photo 3
Method Of Treating Schizophrenia Prodrome

Method Of Treating Schizophrenia Prodrome

US Patent:
8492418, Jul 23, 2013
Filed:
Apr 11, 2006
Appl. No.:
11/918287
Inventors:
Scott W. Woods - East Haven CT, US
Assignee:
Yale University - New Haven CT
International Classification:
A61K 31/195, A61K 31/221, A61K 31/42, A61P 25/18
US Classification:
514380, 514551, 514561
Abstract:
The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixtures thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.